Skip to main content

Table 1 Role of Plk1 as prognostic marker in clinical tumors

From: Polo-like kinase 1 as target for cancer therapy

Tumor type Number of tumors Method Result Reference
colorectal cancer 78 immunohistochemistry expression in tumors higher than in normal tissues [8]
    significant correlations with invasion and Duke’s stage  
advanced rectal cancer 76 immunohistochemistry significant correlations with tumor regression [9]
  20 mRNA microarray and long-term clinical outcome  
colorectal carcinoma 56 immunohistochemistry expression in tumors higher than in normal tissues [10]
    significant correlations with Duke’s stage, tumor size,  
    invasion, and lymph node metastasis  
gastric adenocarcinoma 208 immunohistochemistry expression in tumors higher than in normal tissues [11]
   RT-PCR   
gastric adenocarcinoma 160 immunohistochemistry prognostic factor for poor survival time [12]
   RT-PCR   
gastric adenocarcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues [13]
    significant correlations with stage, nodal status and diffuse  
    growth pattern, no correlation to lymph node metastasis  
hepatocellular carcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues, [14]
  111 RT-PCR significant correlations to venous invasion, tumor nodules  
    and Edmondson grade, prognostic factor for poor survival time  
hepatoblastoma 74 RT-PCR expression in tumors higher than in normal tissues [15]
non-small cell lung 100 immunohistochemistry expression in tumors higher than in normal tissues [16]
cancer    significant correlations with stage, grade and lymph  
    node metastasis  
melanoma 36   significant correlation with metastasis  
astrocytic tumors   immunohistochemistry significant correlation with grade of anaplasia [17]
non-Hodgkin lymphoma 66 immunohistochemistry prognostic factor for poor survival time [18]
non-Hodgkin lymphoma 118 immunohistochemistry significant correlations with grade,  
    prognostic factor for poor survival time  
cutaneous T-cell 49 immunohistochemistry expression in tumors higher than in patch and [19]
lymphoma    plaque-stage lesions  
muliple myeloma 188 immunohistochemistry prognostic factor for poor survival time [20]
breast carcinoma 135 immunohistochemistry expression in tumors higher than in normal tissues [21]
    no correlation with 10 year survival time  
breast carcinoma 3093 immunohistochemistry no correlation with 10 year survival time [22]
ovarian tumors 17 immunohistochemistry significant correlation with grade [23]
ovarian tumors 107 immunohistochemistry expression in high malignant tumors than in low [24]
    malignant tumors, prognostic factor for poor survival time  
endometrial tumors 20 immunohistochemistry significant correlation with grade [25]
cervical carcinoma 36 immunohistochemistry significant correlation with tumor size [26]